Christopher M. Gallagher, MD, discusses unmet needs surrounding the use of antibody-drug conjugates, as well as questions remaining with other approved agents in breast cancer.
Christopher M. Gallagher, MD
Advertisement
Articles by Christopher M. Gallagher, MD
Christopher M. Gallagher, MD, discusses treatment sequencing considerations with antibody-drug conjugates in patients with HER2-low metastatic breast cancer.
Advertisement
Latest Updated Articles
Dr Gallagher on Unmet Needs With ADCs in Breast CancerPublished: December 1st 2023 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
Multi-Omic Profiling Reveals Genetic and Epigenetic Pirtobrutinib Resistance Pathways in MCL
5